| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
36,811,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux (GERD) disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). Co.'s lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a noninvasive office procedure, serving as a screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
37,781 |
71,645 |
| Total Sell Value |
$0 |
$0 |
$54,809 |
$112,492 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
6 |
7 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pavmed Inc. |
10% Owner |
– – • |
2024-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,331,747) |
31,302,444 |
|
- |
|
| Pavmed Inc. |
10% Owner |
– – • |
2024-01-26 |
4 |
A |
$1.40 |
$4,675,474 |
D/D |
3,331,771 |
34,634,191 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2023-09-26 |
4 |
AS |
$1.43 |
$43,173 |
D/D |
(29,747) |
101,592 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2023-09-25 |
4 |
AS |
$1.43 |
$286 |
D/D |
(200) |
131,339 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2023-09-21 |
4/A |
AS |
$1.44 |
$144 |
D/D |
(100) |
131,539 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2023-09-21 |
4 |
S |
$1.44 |
$144 |
D/D |
(100) |
131,539 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2023-09-20 |
4/A |
AS |
$1.44 |
$5,531 |
D/D |
(3,817) |
131,639 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2023-09-20 |
4 |
S |
$1.44 |
$5,531 |
D/D |
(3,817) |
131,639 |
|
- |
|
| Pavmed Inc. |
10% Owner |
– – • |
2022-11-30 |
4/A |
A |
$1.66 |
$6,474,459 |
D/D |
3,375,230 |
31,302,420 |
|
- |
|
| Pavmed Inc. |
10% Owner |
– – • |
2022-11-30 |
4 |
A |
$1.66 |
$6,474,459 |
D/D |
3,375,230 |
42,483,475 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2022-09-20 |
4 |
S |
$1.70 |
$57,683 |
D/D |
(33,864) |
135,456 |
|
- |
|
| Oneil Shaun |
Chief Operating OfficerOfficer |
• – – |
2022-03-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
120,000 |
|
- |
|
| Mcgrath Dennis M |
Chief Financial Officer |
• – – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
624,400 |
|
- |
|
| Aklog Lishan |
Chief Executive Officer |
• • – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
624,400 |
|
- |
|
| Sparks Ronald M |
Director |
– • – |
2021-10-18 |
4 |
A |
$0.00 |
$0 |
D/D |
84,660 |
84,660 |
|
- |
|
| Pavmed Inc. |
10% Owner |
– – • |
2021-10-18 |
4 |
B |
$14.00 |
$7,999,992 |
D/D |
571,428 |
27,927,190 |
2.45 |
- |
|
| Pavmed Inc. |
10% Owner |
– – • |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,355,762 |
|
- |
|
| Lapidus Stanley |
Director |
– • – |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
169,320 |
|
- |
|
| Cox James L |
Director |
– • – |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
169,320 |
|
- |
|
| Angagaw Aster |
Director |
– • – |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
84,660 |
|
- |
|
| Sokolov Jacque J |
Director |
– • – |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
84,660 |
|
- |
|
| Mcgrath Dennis M |
Chief Financial OfficerOfficer |
• – – |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
564,400 |
|
- |
|
| Aklog Lishan |
Chief Executive OfficerOfficer |
• • – |
2021-10-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
564,400 |
|
- |
|
23 Records found
|
1
|
Page 1 of 1 |
|
|
